Dogwood Therapeutics, Inc. (DWTX NASDAQ) stock market data APIs
$2.8146
0.04(1.4%)
as of January 30, 2026
Try our APIs with
free plan!
Dogwood Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Prev. Close
2.8146
Open
2.8564
High
3.0704
Low
2.7613
52 wk Range
2.6-14.69
Market Cap
89 510 K
Shares Outstanding
29 728 K
EPS
-8.2
Beta
1.923
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Dogwood Therapeutics, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dogwood Therapeutics, Inc. data using free add-ons & libraries
Get Dogwood Therapeutics, Inc. Fundamental Data
Dogwood Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-07
- EPS/Forecast: -0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dogwood Therapeutics, Inc. News
New
Halneuron Shows Pain Relief Separation In Interim Phase 2b Trial
(RTTNews) - Dogwood Therapeutics Inc. (DWTX) yesterday announced positive interim results from its ongoing Phase 2b study of Halneuron in chemotherapy-induced neuropathic pain, with treated patients d...
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far belo...
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured e...
Dogwood Secures License To Develop Serpin Pharma's IV Formulation Of SP16
(RTTNews) - Dogwood Therapeutics, Inc. (DWTX) said, in an all-stock transaction, it has secured a royalty free, global license to develop Serpin Pharma's intravenous formulation of SP16 to manage canc...
Get Dogwood Therapeutics, Inc. fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
